fondaparinux eu filing, page-62

"Dr Reddy's Laboratories: Hold"

"Growth rates in the coming year would be impressive, but it may not be easy for DRL to sustain its performance thereon. While shared FTF launch of generic Geodon and higher contribution from generic Arixtra sales would give a leg up to its revenues, higher competition in its other launches would curtail the growth.

DRL has already garnered 18 per cent market share in generic Arixtra and expects to target the hospital segment once the production stabilises. Generic Arixtra is manufactured using a method developed by Alchemia, and marketed by Dr Reddy's. Only a month ago, Alchemia said that it was selling more than $1.4 million per week worth of the drug in the US market since its launch in July 2011. In end-March, DRL made a regulatory submission covering generic Arixtra in Europe. While the approval is at least a year away, the timely filing provides confidence."


http://www.thehindubusinessline.com/features/investment-world/stock-insight/article3314905.ece